Author: Benzinga Newsdesk | November 06, 2025 07:22am
Neumora Therapeutics (NASDAQ:NMRA) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.33) by 4.79 percent. This is a 22.22 percent increase over losses of $(0.45) per share from the same period last year.